PCM
NYMX

Prelude Capital Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Prelude Capital Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,560
Closed -$13K – 2208
2014
Q2 		$13K Buy
+2,560
New +$13.2K ﹤0.01% 1794

Other funds holding NYMX

AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prelude Capital Management's NYMX Position: Q3 2014 in Review

Prelude Capital Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2014, closing a stake of 2,560 shares — an estimated $13K sold.

Prelude Capital Management first reported a position in NYMX in Q2 2014 and held it in 1 quarter. The position peaked at $13K in Q2 2014. 29 funds tracked by Wall St. Rank hold NYMX as of Q3 2014.

  • Prelude Capital Management reported no remaining Nymox Pharmaceutical Corp position as of Q3 2014 after selling out during the quarter.
  • Prelude Capital Management sold 2,560 Nymox Pharmaceutical Corp shares in Q3 2014, an estimated $13K.
  • Prelude Capital Management first reported a position in Nymox Pharmaceutical Corp in Q2 2014 and held it in 1 quarter.
  • Prelude Capital Management's Nymox Pharmaceutical Corp position peaked at $13K in Q2 2014.
  • 29 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2014.

Based on Prelude Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.